Status:
TERMINATED
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
Eligibility Criteria
Inclusion
- Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney.
- Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure.
Exclusion
- Patient has received or is receiving an organ transplant other than kidney
- Patient has received a kidney transplant from a cadaveric donor \>= 60 years of age.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00282230
Start Date
November 1 2003
End Date
October 1 2005
Last Update
June 7 2012
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Los Angeles, California, United States, 90057
3
San Diego, California, United States, 92123
4
Denver, Colorado, United States, 80262